Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
Por:
Hong J, Novick D, Montgomery W, Moneta MV, Dueñas H, Peng X and Haro JM
Publicada:
16 oct 2015
Categoría:
Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Resumen:
To assess the levels of quality of life (QoL) in major depressive disorder (MDD) patients treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic clinical setting mostly in the Middle East, East Asia, and Mexico.
Filiaciones:
Hong J:
Eli Lilly and Company, Windlesham, Surrey, UK
Novick D:
Eli Lilly and Company, Windlesham, Surrey, UK
Montgomery W:
Eli Lilly Australia Pty Ltd, Sydney, NSW, Australia
Moneta MV:
Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain
Dueñas H:
Eli Lilly de Mexico, Mexico City, Mexico
Peng X:
Eli Lilly and Company, Indianapolis, IN, USA
Haro JM:
Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain
Open Access
|